Member Info for CHELSEA7

14/14.7

Another 62,500 delayed sell from 09.38ish at 14.20

Look like a sell from 09.19 at 14.5p

Well we are 25% up on the placing price in 11 trading days. Very grateful for that, and �11m in the bank. Happy. Have a great day all.

On Ask

23/05/2018 08:01 30,000 15.4 23/05/2018 08:00 3,241 15.12

Paid x2

14.7/15.5

14.5/15.5

14.5/15.3

Wins up to 14.3 on bid, CFEP now 14.5p

Getting stronger as we speak.

Not in the one code, but hey

Reply | Recommend 1 | ReportCHELSEA7 Posts: 31,954 Premium Chat Member Off Topic Opinion: Strong Buy Price: 14.70 SssshhhTue 14:5310:32 :14.64,1 Trade 0.15 A rarity here!!!

Scancell Holdings Plc ("Scancell" or the "Company") Scancell announces grant of European patent for its Moditope� immunotherapy platform Scancell Holdings plc, the developer of novel immunotherapies for the treatment of cancer, confirms that following its announcement on 9 February 2018, the European Patent Office will grant a European Patent for the Company's Moditope� immunotherapy platform with effect from 13 June 2018. The patent will provide broad protection for the Company's pipeline of Moditope� vaccines, including any citrullinated epitopes for the treatment of cancer, in all major European territories including: Austria, Belgium, Switzerland, Germany, Denmark, Spain, Finland, France, United Kingdom, Ireland, Italy, Netherlands, Norway, Poland, Portugal, Sweden and Turkey. Counterparts to this patent have been filed in Australia, Brazil, Canada, China, Hong Kong, Japan, South Korea, South Africa and the US. Professor Lindy Durrant, Chief Scientific Officer of Scancell, commented: "This is a key patent for Scancell and endorses our work in identifying a new class of cancer vaccine capable of inducing potent immune responses to stress-induced post-translational modifications (siPTM), in this case, through citrullination of cellular proteins. We are now well positioned to develop a pipeline of new Moditope� therapies with the potential to address the unmet need across a broad range of hard to treat cancers including ovarian, triple negative breast cancer and sarcoma."

Professor Lindy Durrant, Chief Scientific Officer of Scancell, commented: "This is a key patent for Scancell and endorses our work in identifying a new class of cancer vaccine capable of inducing potent immune responses to stress-induced post-translational modifications (siPTM), in this case, through citrullination of cellular proteins. We are now well positioned to develop a pipeline of new Moditope� therapies with the potential to address the unmet need across a broad range of hard to treat cancers including ovarian, triple negative breast cancer and sarcoma."

https://www.investegate.co.uk/oncimmune-hldngs-plc/rns/oncimmune-publishes-study-in-plos-one/201805230700119501O/

Congratulations ALL.................................................. https://www.investegate.co.uk/scancell-hlds--sclp-/rns/grant-of-european-patent-for-moditope-platform/201805230700129505O/

Considering H has taken some criticism for not explaining commercialism to everybodies liking who remembers this?? Just 11 minutes lomg, worth a recap. """""http://www.proactiveinvestors.co.uk/companies/stocktube/8748/new-scancell-chief-sets-out-his-vision-to-commercialise-groundbreaking-cancer-treatments-8748.html"""""

Just a little reminder.......................................... Moditope� Stimulating the production of killer CD4+ T cells that destroy tumours without toxicity Moditope� represents a completely new class of potent and selective immunotherapy agents which could have a profound effect on the way that cancer immunotherapies are developed. It acts by stimulating the production of CD4+ T cells using citrullinated tumour-associated peptide epitopes which overcome self-tolerance and destroy tumour cells. The technology overcomes the immune suppression induced by tumours themselves without the need for checkpoint blockade inhibitors, thereby allowing activated T cells to seek out and kill tumour cells that would otherwise be hidden from the immune system. It has the potential to be used to develop multiple immunotherapeutic agents for a wide range of different cancers. A broad patent has been filed to protect this platform covering the use of multiple tumour-associated modified epitopes for the treatment of cancer. Modi-1 Scancell�s Moditope� immunotherapy platform is based on exploiting the normal immune response to stressed cells, which is largely mediated by CD4+ T cells, and harnessing this mechanism to eradicate cancer cells. Scancell�s first target for Moditope� is vimentin � a major cytoskeletal protein found in mesenchymal cells. Many epithelial tumours switch from expression of cytokeratin to vimentin during metastasis in a process known as epithelial mesenchymal transition (EMT); this change in phenotype enables the cell to become mobile and metastasize to new locations in the body. Scancell has now selected two modified vimentin peptides in which the arginine residues have been substituted by citrulline to form the basis of its first Moditope� development candidate, Modi-1. The inclusion of additional modified peptides from other Moditope� target proteins into Modi-1 is currently under review. Animal studies have shown that the two vimentin peptides stimulate potent anti-tumour responses and leads to significant improvements in survival, suggesting that the Modi-1 product could have outstanding potential as a novel immunotherapy. Immune response studies with cells isolated from cancer patients have confirmed that T cell responses were stimulated by both modified vimentin peptides. Optimisation studies have identified the adjuvant, dose and administration route for testing Modi-1 in the First in Man study. In animal studies, an aggressive tumour cell line confirmed that the two vimentin peptides eradicate tumour cells in a therapeutic, and therefore clinically relevant, setting. Remarkably, these responses were evident when tumours had reached a late stage of development. Moditope� vaccines have the potential to treat a wide variety of cancers. Scancell is currently further evaluating the initial indications for the first clinical trial with Modi